Dataset: Microarray gene expression profiling of cardiac genes at the onset of heart failure
Atherosclerosis and pressure overload are major risk factors for the development of heart failure in patients. Cardiac hypertrophy often...
Atherosclerosis and pressure overload are major risk factors for the development of heart failure in patients. Cardiac hypertrophy often precedes the development of heart failure. However, underlying mechanisms are incompletely understood. To investigate pathomechanisms underlying the transition from cardiac hypertrophy to heart failure we used experimental models of atherosclerosis- and pressure overload-induced cardiac hypertrophy and failure, i.e. apolipoprotein E (apoE)-deficient mice, which develop heart failure at an age of 18 months, and non-transgenic C57BL/6J (B6) mice with heart failure triggered by 6 months of pressure overload induced by abdominal aortic constriction (AAC). The development of heart failure was monitored by echocardiography, invasive hemodynamics and histology. The microarray gene expression study of cardiac genes was performed with heart tissue from failing hearts relative to hypertrophic and healthy heart tissue, respectively. The microarray study revealed that the onset of heart failure was accompanied by a strong up-regulation of cardiac lipid metabolism genes involved in fat synthesis, storage and oxidation. Microarray gene expression profiling was performed with heart tissue isolated from (i) 18 month-old apoE-deficient mice relative to age-matched non-transgenic C57BL/6J (B6) mice, (ii) 6 month-old apoE-deficient mice with 2 months of chronic pressure overload induced by abdominal aortic constriction (AAC) relative to sham-operated apoE-deficient mice and nontransgenic B6 mice, (iii) 10 month-old B6 mice with 6 months of AAC relative to sham-operated B6 mice, and (iv) 5 month-old B6 mice with 1 month of AAC relative to age-matched B6 mice.
- Species:
- mouse
- Samples:
- 18
- Source:
- E-GEOD-25765
- Updated:
- Dec.12, 2014
- Registered:
- Nov.11, 2014
Sample | DISEASE STATUS | AGE | GENOTYPE/VARIATION |
---|---|---|---|
GSM632859 | failing, atherosclerosis | 18 months | apoE-deficient |
GSM632859 | failing, atherosclerosis | 18 months | apoE-deficient |
GSM63286 | control | 18 months | wild type |
GSM63286 | control | 18 months | wild type |
GSM632863 | failing, 2 months of AAC and atherosclerosis | 6 months | apoE-deficient |
GSM632863 | failing, 2 months of AAC and atherosclerosis | 6 months | apoE-deficient |
GSM632865 | control, atherosclerosis | 6 months | apoE-deficient |
GSM632865 | control, atherosclerosis | 6 months | apoE-deficient |
GSM632867 | control | 6 months | wild type |
GSM632867 | control | 6 months | wild type |
GSM632869 | failing, 6 months of AAC | 10 months | wild type |
GSM632869 | failing, 6 months of AAC | 10 months | wild type |
GSM63287 | control | 10 months | wild type |
GSM63287 | control | 10 months | wild type |
GSM632873 | hypertrophic, 1 month of AAC | 5 months | wild type |
GSM632873 | hypertrophic, 1 month of AAC | 5 months | wild type |
GSM632875 | control | 5 months | wild type |
GSM632875 | control | 5 months | wild type |